Our pipeline summary is available to download (PDF 117 kb). This information was updated after our fourth quarter and full year results 2009, announced Thursday, 28 January 2010.
Please use the expanding table below to navigate the HTML version of the pipeline summary.Comments
As disclosure of compound information is balanced by the business need to maintain confidentiality,
information in relation to some compounds listed here has not been disclosed at this time.
Compounds in development are displayed by phase.
Key:
MAA – Marketing Authorisation Application (Europe).
NDA – New Drug Application/Biologics Licensing Application (USA).
Not signed in
Page tools
Share price
- London
-
29.44 GBP - New York
-
44.38 USD - Stockholm
-
315.40 SEK
At 11-Mar-2010 10:44 GMT
Detailed share priceIntroduction to AstraZeneca
Our responsibility
We continue to communicate openly on a range of issues, including:
